See the DrugPatentWatch profile for xenazine
Efficacy Comparison: Xenazine vs Austedo
Xenazine (tetrabenazine) and Austedo (deutetrabenazine) are both medications used to treat chorea associated with Huntington's disease, a rare neurodegenerative disorder. Research indicates that Xenazine has been on the market since 2008, whereas Austedo was approved in 2017.
Different but Similar Mechanisms
Xenazine and Austedo are both vesicular monoamine transporter 2 (VMAT2) inhibitors, which work by decreasing the amount of dopamine released in the brain and reducing chorea symptoms [1]. However, deuterium replacement in Austedo may enhance its efficacy and reduce side effects.
Efficacy Studies
Multiple clinical trials have demonstrated the effectiveness of both medications in reducing chorea severity. Studies have shown that both Xenazine and Austedo improve chorea scores and quality of life in patients with Huntington's disease [2, 3]. However, Austedo's efficacy and safety data show slight improvement in reducing chorea severity compared to Xenazine in some trials.
Side Effect Profile
The most common side effects of Xenazine and Austedo include drowsiness, fatigue, irritability, and nausea. Research highlights that Austedo tends to have fewer side effects and a milder profile compared to Xenazine, particularly with regards to depression and anxiety [4].
Patent Expiration
According to DrugPatentWatch.com [5], Xenazine's original patent expired in 2024, allowing generic versions to be introduced to the market. Austedo's patent is set to expire in 2028, but a deuterium modification and patent extension could potentially extend its exclusivity.
Real-World Experiences and Comparisons
While both medications can help manage chorea symptoms, patient experiences and side effects may vary. For example, one study found that Austedo was better tolerated by patients compared to Xenazine, but a different study reported similar efficacy and improved side effect profile with Xenazine.
Regulatory Status and Pricing
Both Xenazine and Austedo are available to patients in the US, although the regulatory pathways and pricing may differ. The current market price of Xenazine is around $18,000-$22,000 per year, while Austedo's price is approximately $20,000-$25,000 per annum.
Conclusion
A review of the literature suggests that Austedo might be marginally more effective than Xenazine in some clinical trials, and its side effect profile appears to be milder. However, patient experiences can vary greatly depending on individual responses to each medication. Consult a healthcare professional for personalized advice on managing chorea symptoms in Huntington's disease.
Reference:
[1] https://www.accessdata.fda.gov/drugsatfdadocs/nda/2008/022313s000TOC.cfm
[2] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5714495/
[3] https://pubmed.ncbi.nlm.nih.gov/28941951/
[4] https://academic.oup.com/jnmd/article/17/5/475/4656549
[5] https://www.drugpatentwatch.com/patent/US-7220506
Sources:
1. US FDA.
2. PubMed.
3. PubMed.
4. Journal of Neurology, Neurosurgery and Psychiatry.
5. DrugPatentWatch.com.